Page last updated: 2024-10-26

disulfiram and Ovarian Neoplasms

disulfiram has been researched along with Ovarian Neoplasms in 7 studies

Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

Research Excerpts

ExcerptRelevanceReference
"Among gynecological cancers, ovarian cancer has a high mortality rate."1.91Proteomics Analysis Revealed Smad3 as a Potential Target of the Synergistic Antitumor Activity of Disulfiram and Cisplatin in Ovarian Cancer. ( Deng, Q; Ding, C; Du, R; Hong, B; Li, K; Nie, J; Qi, J; Sun, F; Sun, Q; Wang, H; Wang, W; Zhong, W, 2023)
" A synergistic treatment with drug supporting activity could maximize the cytotoxic effects of chemotherapeutic agents on tumor cells while decreasing the dosage of each drug to potentially reduce toxicity."1.72Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death. ( Guo, F; Kaufmann, AM; Sehouli, J; Yang, Z, 2022)
"Disulfiram (DSF) is a drug used for treatment of alcoholism that has also displayed promising anti-cancer activity."1.51Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation. ( Albers, AE; Guo, F; Kaufmann, AM; Kulbe, H; Sehouli, J; Yang, Z, 2019)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (42.86)24.3611
2020's4 (57.14)2.80

Authors

AuthorsStudies
Guo, F2
Yang, Z2
Sehouli, J2
Kaufmann, AM2
Du, R1
Sun, F1
Li, K1
Qi, J1
Zhong, W1
Wang, W1
Sun, Q1
Deng, Q1
Wang, H1
Nie, J1
Ding, C1
Hong, B1
Gan, Y1
Liu, T1
Feng, W1
Wang, L1
Li, LI1
Ning, Y1
Kulbe, H1
Albers, AE1
Torralba, M1
Farra, R1
Maddaloni, M1
Grassi, M1
Dapas, B1
Grassi, G1
Jiao, Y1
Hannafon, BN1
Zhang, RR1
Fung, KM1
Ding, WQ1
O'Brien, A1
Barber, JE1
Reid, S1
Niknejad, N1
Dimitroulakos, J1

Other Studies

7 other studies available for disulfiram and Ovarian Neoplasms

ArticleYear
Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death.
    Current oncology (Toronto, Ont.), 2022, 04-16, Volume: 29, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Disulfiram; Female; Humans; Necrosis; Neoplastic Stem C

2022
Proteomics Analysis Revealed Smad3 as a Potential Target of the Synergistic Antitumor Activity of Disulfiram and Cisplatin in Ovarian Cancer.
    Anti-cancer agents in medicinal chemistry, 2023, Volume: 23, Issue:15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disulfir

2023
Drug repositioning of disulfiram induces endometrioid epithelial ovarian cancer cell death via the both apoptosis and cuproptosis pathways.
    Oncology research, 2023, Volume: 31, Issue:3

    Topics: Animals; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Death; Copper; Disulfiram; Drug Repositionin

2023
Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 118

    Topics: Aldehyde Dehydrogenase; Apoptosis; Cell Cycle; Cell Line, Tumor; Cisplatin; Copper; Disulfiram; Fema

2019
Drugs Repurposing in High-Grade Serous Ovarian Cancer.
    Current medicinal chemistry, 2020, Volume: 27, Issue:42

    Topics: Antineoplastic Agents; Disulfiram; Drug Repositioning; Female; Humans; Ovarian Neoplasms; Pharmaceut

2020
Docosahexaenoic acid and disulfiram act in concert to kill cancer cells: a mutual enhancement of their anticancer actions.
    Oncotarget, 2017, Mar-14, Volume: 8, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Disulfiram; D

2017
Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3.
    Anticancer research, 2012, Volume: 32, Issue:7

    Topics: Activating Transcription Factor 3; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; C

2012